The primary objectives of the biostatistics as core resource in the GI Cancer SPORE are proper design of studies, ongoing monitoring, ensuring data quality and completeness in ongoing studies, state-of-the-art statistical analyses of results, and assistance to investigators in interpreting and presenting result. The guiding philosophy will be to keep quantitative aspects of the research closely tied to the specific aims, and to have the collaboration of the investigator and biostatistician such that the biologic knowledge of the researcher plays an integral part in shaping the statistical analyses. To achieve these objectives, the core biostatistician will be available to SPORE investigators at all phases of their projects. Discussion of study aims, appropriate design parameters (i.e. study structure and sample size), interim analyses, analytical plans, interpretation of results and guidance for publication will be provided as needed. All analyses will use the most current methods and will be conducted or supervised by the statistician. Because many of these analyses are exploratory and are meant to assess new methods, there will be emphasis on estimation of important clinics and laboratory parameters with confidence intervals and likelihood/Bayesian methodology rather than statistical, hypothesis testing. The core statistician has experience in a number of areas of particular value to core investigators; inference in situations where there is relatively little empirical data, analysis of clinical research with small numbers of subjects, gene expression in GI tumors, and evaluation of cancer screening tests. He will be assisted by an experienced member of the Oncology/Biostatistics staff, who will have the responsibility for performing most of the statistical analyses under his supervision.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA062924-08S1
Application #
6496916
Study Section
Project Start
2001-05-04
Project End
2002-06-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kuboki, Yuko; Fischer, Catherine G; Beleva Guthrie, Violeta et al. (2018) Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. J Pathol :
Zhang, Jiajia; Quadri, Shafat; Wolfgang, Christopher L et al. (2018) New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 6:
Hata, Tatsuo; Suenaga, Masaya; Marchionni, Luigi et al. (2018) Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. Am J Pathol 188:1723-1733
Noë, Michaël; Rezaee, Neda; Asrani, Kaushal et al. (2018) Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology. Am J Pathol 188:1530-1535
Schunke, Kathryn J; Rosati, Lauren M; Zahurak, Marianna et al. (2018) Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Adv Radiat Oncol 3:42-51
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Staedtke, Verena; Bai, Ren-Yuan; Kim, Kibem et al. (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564:273-277
Deng, Yang; Tu, Huakang; Pierzynski, Jeanne A et al. (2018) Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Eur J Cancer 92:20-32
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772

Showing the most recent 10 out of 883 publications